|1.||Chou, Ting-Chao: 12 articles (02/2013 - 12/2002)|
|2.||Su, Tsann-Long: 10 articles (02/2013 - 09/2004)|
|3.||Chen, Ching-Huang: 7 articles (02/2013 - 09/2004)|
|4.||Dong, Huajin: 7 articles (07/2012 - 10/2005)|
|5.||Kakadiya, Rajesh: 6 articles (02/2013 - 08/2009)|
|6.||Shah, Anamik: 6 articles (02/2013 - 08/2009)|
|7.||Lee, Te-Chang: 6 articles (02/2013 - 08/2009)|
|8.||Zhang, Xiuguo: 6 articles (01/2011 - 06/2005)|
|9.||Drewe, John: 6 articles (07/2009 - 08/2005)|
|10.||Tseng, Ben: 6 articles (07/2009 - 08/2005)|
01/01/1998 - "The same relative differences were shown for the therapeutic efficacy of these three analogues at equitoxic doses in studies with the human MX-1 and LX-1 tumors and the human A549 NSC lung tumor xenografted in nude mice. "
08/01/2012 - "This study confirms the capability of tumor cells to secrete IFN-I, demonstrated by biological IFN-I activity of cultured cells and immunohistochemical expression of Mx-1 protein. "
02/01/2012 - "Stabilized palifosfamide administered by optimized regimens suppressed MX-1 tumor growth (P<0.05) by greater than 80% with 17% complete antitumor responses and up to three-fold increase in time to three tumor doublings over controls. "
02/06/2007 - "Specific high-affinity binding sites for GHRH were found on MX-1 tumor membranes using ligand competition assays with (125)I-labeled GHRH antagonist JV-1-42. "
01/01/2006 - "The relationship between drug release rates and anti-tumor efficacy was evaluated using a MX-1 human mammary tumor model. "
06/01/2011 - "CrA was active as a single agent in the MX-1 breast carcinoma, but did not exhibit statistically significant activity as a single agent in the Colo-205 colon carcinoma under the doses and schedules used in the study. "
01/01/1995 - "The present investigation is concerned with the morphological features of the human breast carcinoma MX-1, transplanted subcutaneously into nude mice. "
01/01/1995 - "The morphology of xenotransplanted human breast carcinoma MX-1 growing in nude mice. "
09/01/1993 - "DROL was more effective than TAM against ER-positive Br-10 breast carcinoma in nude mice, but neither drug had effects on ER-negative MX-1 breast carcinoma. "
04/15/1989 - "on Days 1,5, and 9 caused regression of the human MX-1 mammary carcinoma implanted under the renal capsule of athymic mice. "
|3.||Breast Neoplasms (Breast Cancer)
02/15/2015 - "Compound 7j was a potent PARP-1 and PARP-2 inhibitor and it could selectively kill the breast cancer cells MX-1 and MDA-MB-468 with mutated BRCA1/2 and PTEN, respectively, in comparison with homologous recombination proficient cell types such as breast cancer cells MDA-MB-231. "
11/01/2013 - "We showed that aurein 1.2, buforin IIb and BMAP-28m exhibited selective cytotoxicity toward MX-1 and MCF-7 breast cancer cells. "
07/01/2009 - "Compound 5d was found to be highly active in the MX-1 breast cancer model. "
11/08/2007 - "Here, we demonstrate that breast cancer cells MX-1 are unable to maintain genome integrity, which results in gross polyploidization. "
04/01/2007 - "In this report, we demonstrate that VNB, as an antimicrotubule agent, induces apoptosis in breast cancer cell line, MX-1 via a mitochondrial pathway."
12/01/1988 - "In particular, this compound exhibited a marked effect against MX-1, a human mammary adenocarcinoma. "
07/01/1989 - "Likewise, ME2303 was more effective against Lu-24 human small cell carcinoma and MX-1 human medullary tubular adenocarcinoma than ADM. "
01/01/1994 - "Against both the MX-1 mammary carcinoma and the DLD-2 colon adenocarcinoma, some measure of schedule dependence was observed; the optimum schedule was daily for 9 days. "
07/31/1990 - "Effect of dietary fat and monoclonal antibody therapy on the growth of human mammary adenocarcinoma MX-1 grafted in athymic mice."
02/01/2003 - "Several tumors were only marginally responsive or totally unresponsive: Mammary Adenocarcinoma-16/C = 0.6 LK; Mammary Adenocarcinoma-17 = no kill; Colon Adenocarcinoma-11 = no kill; L1210 leukemia = 1.3 LK; Human Prostate PC-3 = 0.5 LK; Human Adenosquamous Lung H125 = no kill; and Human Breast Adenocarcinoma MX-1 = 0.9 LK. "
07/07/1998 - "Finally, in vivo combination studies demonstrated that nontoxic doses of the ardeemins with DX significantly improved the chemotherapeutic effects in B6D2F1 mice bearing DX-resistant P388 leukemia, and nude mice bearing human MX-1 mammary carcinoma xenografts. "
02/01/2002 - "Included are the intravenously-implanted murine P388 leukemia, the subcutaneously-implanted murine B16 melanoma and two examples of subcutaneously-implanted human tumor xenografts, the LX-1 (lung) and MX-1 (breast) tumors."
07/01/1990 - "4-Amino-3-fluoro-1-beta-D-ribofuranosyl-2(1H)-pyridinone (1) displayed good activity against intraperitoneally implanted P388 leukemia in mice, but it was devoid of activity against M5076 sarcoma, amelanotic (LOX) melanoma xenograft, and subrenal capsule human mammary carcinoma MX-1 xenograft in mice. "
08/01/1986 - "It showed superior activity to cisplatin against P388/cisplatin and like cisplatin showed significant and reproducible activity against the ip implanted B16 melanoma, ip implanted M5076 sarcoma, ip implanted P388 leukemia, and MX-1 human breast xenograft implanted under the renal capsule. "
07/01/2001 - "Several of the acyl derivatives were found to be superior to DM-PEN against MX-1, human ZR-75-1 breast tumor, human U251 CNS tumor and the P388 leukemia parent cell line and lines resistant to cyclophosphamide and carmustine. "
|5.||Complement System Proteins (Complement)
|9.||soblidotin (TZT 1027)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)